IMD treatment significantly reduced the occurrence of AAA to 46.2% (P<0.05) and N-[N-(3,5-difluorophenacetyl)-Lalany]-S-phenylglycine t-butyl ester (DAPT) (Notch1 pathway inhibitor) had a similar effect as IMD, with 53.3% AAA morbidity (P<0.05) (Figure 3A, 3B). The gene discussed is NOTCH1; the disease is triple-A syndrome.